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Bifidobacterium is the most predominant in the intestine of breast-fed 
infants and beneficial for the maintenance of the balanced microflora in 
the gut. Human milk oligosaccharides (HMO) is the third most 
common solid component (15 g/L) in human milk and contains 
abundant fucosylated oligosaccharides (FO). Therefore, 
Bifidobacterium which can use fucosylated HMO is expected to be 
selectively enriched in the intestine of breast-fed infants. The utilization 
of human milk saccharides (HMS) and artificial fucosylated 
oligosaccharides (2-fucosyllactose, 3-fucosyllactose) by various 
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Bifidobacterium strains were assessed. B. bifidum BGN4 showed 
specific growth in the presence of 2FL or 3FL. Using the annotated 
sequences of two theoretical α-L-fucosidase genes (BBB_0176 and 
BBB_1341) in the genome of B. bifidum BGN4, those genes have been 
cloned in E. coli for the expression and characterization of the 
corresponding enzymes. AFL03772, product of BBB_0176, hydrolyzed 
α-(1→2) and α-(1→3) linkages of 2- and 3-fucosyllactoses; whereas 
AFL04933, product of BBB_1341, hydrolyzed α-(1→3) linkage of 3-
fucosyllactose. Based on the results obtained in this study, B. bifidum 
BGN4 has been concluded to have two α-L-fucosidase enzymes to 
hydrolyze FO. Therefore, B. bifidum BGN4 may be used as beneficial 
bacteria which can preferentially grow in the intestine of the breast-fed 
infants. 
 
Keywords : Bifidobacterium bifidum BGN4, α-L-fucosidase, 
fucosylated HMO utilization. 
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Human milk is a sole nutrient source and best food for the infants. It is 
composed of unique proteins, carbohydrates, lipids, minerals, and 
vitamins which were adapted to satisfy the nutritional and 
immunological needs of infants. Also it provides wide range of 
beneficial effects to infants [24, 25, 29].  
Human milk contains human milk oligosaccharides (HMO) as the 
third most common solid component (15 g/L). The breast milk of the 
other species including bovine milk also has oligosaccharides but 
human milk has significantly more abundant and diverse 
oligosaccharides than those of the other milk [22, 23]. HMO is mainly 
composed of different monosaccharides (D-glucose, D-galactose, N-
acetylglucosamine, L-fucose, and sialic acid). Most HMO have lactose 
at the reducing end, which generally sialylated (3-sialyllactose, 6-
sialyllactose) or fucosylated (2-fucosyllactose, 3-fucosyllactose) [5]. 
HMO contains different oligosaccharide components and various 
structures among the individuals, Lewis blood type, and during the 
course of lactation [26, 27]. Among the 200 different identified HMO, 
137 HMO were fucosylated and proportion of fucosylated 
oligosaccharide (FO) is approximately 75% [13]. In contrast, the most 
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abundant oligosaccharides of bovine milk contain sialylated 
oiligosaccharides [22, 28]. Therefore, the abundance of FO is a special 
characteristic of HMO.  
FO, the major component of HMO provides some beneficial effects to 
infants. Various pathogens recognize fucosylated glycans of the 
epithelial cell as a receptor. FO can act like a cell surface receptor to the 
various pathogens [5]. By blocking the adhesion of the various 
pathogens to the epithelial cell glycan layer, FO can protect the 
intestinal tract of the infants from the attack of the pathogens [5, 12, 14]. 
Moreover, FO exerts prebiotic effects [21]. Prebiotics is defined as 
“selectively fermented ingredient that results in specific changes in the 
composition and/or activity of the gastrointestinal microbiota, thus 
conferring benefit(s) upon host health” by Gibson et al [7]. The 
fucosylated residues of FO protect themselves from digestive enzymes 
[8]. The FO reach large intestine, instead of being digested and 
absorbed as a nutrient, to promote the selective growth of 
Bifidobacterium which is a well-known beneficial bacteria [4, 5]. The 
selectively promoted beneficial bacteria inhibit the growth of pathogens 
either by lowering the intestinal pH or through nutrient competition [4, 
8].  
For the selective growth in the intestine with FO, the bacteria need 
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ability to hydrolyze fucosylated residue of FO and use the released 
sugars as energy sources. Accordingly, α-L-fucosidase, an enzyme to 
hydrolyze fucosyl residue of HMO is essential for the use of FO [3]. 
 
Bifidobacterium is known to be the main utilizer of HMO, which 
contributed to the abundance of bifidobacteria in the intestinal tract of 
the breast-fed infants compared to adults or formula-fed infants [15]. In 
the present study, to identify specific Bifidobacterium with high ability 
to use fucosylated HMO, five strains of bifidobacteria were assessed 
the utilization of HMO and FO. Among them, B. bifidum BGN4 which 
showed the best growth on FO was chosen and its two α-L-fucosidase 















All reagents were purchased from Sigma-Aldrich (St. Louis, MO, 
USA) unless specifically described. 2-fucosyllactose (2FL) and 3-




1. Bacterial strains and culture conditions 
 
The bacterial strains used in this work are listed in Table 1. 
Bifidobacterium strains (B. bifidum BGN4, B. longum RD47, B. 
adolescentis KCTC 3216, B. infantis KCTC 3249, B. breve KCTC 
3419) were obtained from the Korean Collection for Type Cultures 
(KCTC, Daejeon, Korea) and Food Microbiology Laboratory Strain 
Collection, Seoul National University. They were grown anaerobically 
in de-Mann-Rogosa-Sharpe (MRS) medium (Becton-Dickinson 
Company, New Jersey, USA) supplemented with 0.05% (w/v) L-
cysteine·HCl at 37°C. To assess the utilization of different carbon 
sources 2FL (6 mg/ml), 3FL (6 mg/ml), human milk saccharides (HMS, 
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20 mg/ml), and bovine milk saccharides (BMS, 20 mg/ml) were added 
into the MRS broth without glucose (KisanBio, Seoul, Korea). 
All broths were filter sterilized through a 0.2 μm PVDF membrane 
(Pall Corporation, NY, USA) and aliquoted into 96-well plates (Costar 
3595, Corning Inc, NY, USA). Milk saccharides were prepared as 
follows. Human breast milk samples were obtained from healthy 
women volunteer as approved by the Institutional Bioethics Review 
Board, Seoul National University (SNUIRB, approval number ; IRB 
No.1411/001-026). The bovine milk was purchased at a local market 
(Seoul Milk, Seoul, Korea). The milk saccharides were separated as 
described by Ward et al [17] with a slight modification. Fifty ml of 
milk was centrifuged at 5,000 × g for 30 min at 4°C, and the fat was 
removed. Then, 2 volume of ethanol was added, and the mixed samples 
were incubated overnight at 4°C with stirring. The precipitate was 
collected by centrifugation at 5,000 × g for 30 min at 4°C and removed. 
The solvent of supernatant was removed by rotary evaporator and 
speed vacuum. The solid content of the solution was used as a crude 
saccharide of human milk and bovine milk. The bacterial growth was 
measured with a microplate reader (Spectra Max 190, Molecular 
devices, CA, USA) set at 600 nm. Three replicates were performed for 
every experimental condition. E. coli and BL21 was grown in Luria-
Bertani (LB) medium (Becton-Dickinson Company, New Jersey, USA) 
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at 37°C with vigorous shaking. The LB medium was supplemented 
with 50 or 100μg/ml ampicillin, 2% agar (Becton-Dickinson Company, 
New Jersey, USA) and 1 mM isopropyl-β-D-thiogalactopyranoside 





















Table 1. Bacterial strains and plasmids used in this study 
Abbreviation Strains & plasmids Characteristics 
Strains   
B. bifidum BGN4 
 
Bifidobacterium bifidum BGN4 Source of two 
α-L-fucosidases 
B. longum RD47 
 












Bifidobacterium longum subsp. 









E. coli BL21 E. coli BL21(λDE3) Expression host 
E0176 
 
E. coli BL21(λDE3) harboring 





E. coli BL21(λDE3) harboring 
pET21 + BBB_1341 
Recombinant  
 

















2. Analysis of carbohydrates during culture by thin layer 
chromatography (TLC) 
 
The carbohydrates in the culture broth were determined by TLC. The 
broths were loaded on the silica gel plate 60 (Merck, Darmstadt, 
Germany). The mobile phase was composed of 1-propanol, distilled 
water (DW), and ethyl acetate (7:2:1, v/v/v). The sulfuric acid–ethanol 
(1:9, v/v) solution was sprayed and dried. The plate was heated at 
120°C, 5 min for visualization. 
 
3. Assessment of the released L-fucose from FO by L-fucose 
colorimetric assay (Fucose assay) 
 
The separated L-fucose from FO by the hydrolytic action of 
Bifidobacterium or α-L-fucosidases was assessed by combination of L-
fucose assay kit (Megazyme, Wicklow, Ireland) and the modified 
colorimetric method of Cohenford et al [6]. The amount of NADPH in 
the L-fucose assay kit’s final reactant was proportional to the sample’s 
L-fucose. The same volume of neocuproine–copper reagent was added 
to the final reactant; the color turned yellow. This yellow color was 
measured by the microplate reader at 455 nm. The neocuproine–copper 
reagent was made by Cohenford et al’s instruction [6]. 
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4. Molecular cloning of two α-L-fucosidase genes from B. bifidum 
BGN4 
 
The bacterial strains and plasmids used in this work are listed in Table 
1. The complete genome sequence of B. bifidum BGN4 (GenBank, 
http://www.ncbi.nlm.nih.gov/genbank/, accession number : CP001361), 
a source of two α-L-fucosidase gene sequences (BBB_0176, 
BBB_1341), was previously reported [19] at the Kyoto Encyclopedia of 
Genes and Genomes (KEGG, http://www.genome.jp/kegg/, Entry 
number : T02135) databases. The expression host E.coli BL21(λDE3) 
(Novagen, WI, USA) and plasmid pET21a(+) (Novagen, WI, USA) 
were employed to clone and express the two α-L-fucosidase genes.  
The chromosomal DNA of B. bifidum BGN4 was isolated with the 
MGTM Cell Genomic DNA Extraction SV kit (MGmed, Seoul, Korea). 
The lysozyme digestion step (resuspend cell pellet with 30 mg/ml 
lysozyme and incubate for 30 min at 37°C) was carried out and 
followed by the manufacturer’s instruction for Gram-negative bacteria. 
The isolated chromosomal DNA was used as template DNA. The 
primers are designed based on the two α-L-fucosidases sequences in the 
full genome of B. bifidum BGN4. The α-L-fucosidase genes were 
amplified by Takara LA Taq™ (Takara, Otsu, Japan) with each primer 
set. The primer sequences used in this work are listed in Table 2. The 
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amplified BBB_0176 and BBB_1341 were purified by PCR/Gel Combo 
Kit (NucleoGen Inc, Daejeon, Korea) and subcloned into pET21a(+) 
vectors with T4 ligase (Promega, WI, USA). The cloning vector for 
BBB_1341 was treated with CIP (calf intestinal alkaline phosphatase, 
Promega, WI, USA) after restriction enzyme digestion and purified by 
PCR/Gel Combo Kit. Each sub-cloned vector was transformed into E. 
coli DH5α and BL21 via heat shock and the CaCl2 method. The 
positive clones were selected by spreading on LB agar plates 
supplemented with 50 µg/ml of ampicillin. The plasmids from the 
selected colonies were purified using a Plasmid Purification Mini Kit 
(NucleoGen Inc, Daejeon, Korea) and confirmed by Bgl II (Promega, 
WI, USA) restriction enzyme digestion. As a marker, 1 kb DNA Ladder 












Table 2. Primer sequences used in this study 
Genes  





5'-CCT AAG CTT CGA TGA AAC 
ATA GAG CGA TGT CAT CG -3' 
afuc0176_R  
(Xho I) 
5'-TAT CTC GAG GCA GGC GGA 





5’- TTA CTC GAG CGA TGC TAC 
ACA CAG CAT CAA GAG GAT G -3’ 
afuc1341_R  
(Xho I) 
5’- TTA CTC GAG GTA CCG GTT 
GGA CTT ACG CTT GGC TTC AA -
3’ 
















5. Assessment of α-L-fucosidase activities in the transformed E.coli 
BL21 
 
BL21 harboring each α-L-fucosidase gene was cultivated in a LB 
medium (containing 100 µg/ml ampicillin) until an OD 600 was 
reached 0.5-0.6. Then, IPTG (1 mM) was added to each culture 
medium and cultivated at 37°C for 6 h with vigorous shaking. After 
cultivation, the cells were harvested by centrifugation at 8,000 × g for 
30 min, 4°C. The 1 g of cell pellet was disrupted by sonication in 5 ml 
of sodium phosphate buffer (pB buffer, 20 mM, pH 7.8) and 
centrifuged at 10,000 × g for 30 min, 4°C. The obtained cell free 
extract was used as a crude enzyme. Cell free extract of BL21 that 
harbored empty vector pET21a(+) was prepared in the same way as a 
negative control. 
For the assessment of α-L-fucosidase activities, 2FL (15 mg/ml), 3FL 
(15 mg/ml), and HMS (300 mg/ml) were added as substrates. Two µl of 
each substrate and 3 µl of each crude enzyme were mixed and 
incubated at 37°C for 30 min. The reaction was stopped by heating at 
98°C for 5 min. The enzyme reactant was analyzed by using TLC and 





6. Purification and characterization of α-L-fucosidases 
 
The 6x his-tag in the pET 21a(+) vector was added to the C terminal 
of each recombinant protein for purification. The crude enzyme was 
loaded onto a HisTrap HP column (GE Healthcare, Uppsala, Sweden), 
and the target protein was eluted with a linear gradient of 0-500 mM 
imidazole in pB buffer (20 mM, pH 7.8) at a 3 ml/min flow rate. The 
eluted fraction was applied to a Superdex-200 HR10/30 column (GE 
Healthcare, Uppsala, Sweden). The column was equilibrated and eluted 
with pB buffer (20 mM, pH 7.8). All chromatography was conducted 
by AKTA Explorer 10 protein purification system (GE Healthcare, 
Uppsala, Sweden). The eluted protein was analyzed by SDS-PAGE to 
determine the purity of the protein. The eluted fractions were 
concentrated by 5K Amicon Ultra centrifugal filter (Millipore, MA, 
USA) when necessary. 
 
7. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE)  
 
SDS-PAGE was carried out with a mini protean 3 cell (Bio-Rad, CA, 
USA), using 10% SDS gel prepared as described by Sambrook et al [1]. 
The prepared protein samples were mixed with protein 2X sample 
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buffer (Elpis Biotech, Daejeon, Korea), boiled for 5 min, and 
electrophoresed at 100 V for 30 min, 200 V for 2-3 h in tris-glycin 
running buffer (Elpis Biotech, Daejeon, Korea). After electrophoresis, 
the gels were stained with Power Stain Brilliant Blue R staining 
solution (Elpis Biotech, Daejeon, Korea) and destained with destaining 
solution (225 ml of methanol, 50 ml of glacial acetic acid, up to 500 ml 
with DW). Prestained protein markers (DokDo-MARK™, 7-240kDa, 
Elpis Biotech, Daejeon, Korea) were used as molecular mass markers. 
 
8. Effects of pH and temperature on α-L-fucosidase activity 
 
AFL03772, the gene product of BBB_0176, was purified by 
aforementioned chromatography in 20 mM pB buffer (pH 7.8). The 
effect of temperature on AFL03772 was evaluated at 25-55°C using 
2FL (15 mg/ml) as substrate. One µl enzyme and 1 µl substrate were 
reacted in 3 µl DW. To determine the effect of pH, 2 µl of enzyme and 
2 µl of substrate were reacted at 37°C in 36 µl of different buffers at pH 
4.05-7.48. Citrate buffer (100 mM) was used for pH 4.05-5.71, and pB 
buffer (20 mM) was used for pH 6.0-7.48. After reaction, the reactants 
were concentrated to 5 µl with speed vacuum. All reactions were 
conducted for 4 h and stopped by heating at 98°C for 5 min. The 
hydrolyzed fucose was determined by the fucose assay. 
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The effect of temperature on AFL04933, the gene product of 
BBB_1341, was evaluated at 25-65°C. One µl of BL21 (E1341) crude 
enzyme in pB buffer (20 mM, pH 7.8) and 4 µl substrate (3FL, 8 mg/ml) 
were reacted. To determine the effect of pH on AFL04933, 2 µl of 
crude enzyme prepared from E1341 in pB buffer (20 mM, pH 10) and 2 
µl substrates (15 mg/ml) were mixed with 36 µl of different pB buffers 
at pH 7-13.8 and incubated at 37°C for 2h and stopped by heating at 
98°C for 5 min. NaOH (5 M) was used for adjusting the pH. After 















3. Results and discussion 
 
Profile of partially purified saccharides of human and bovine milk  
 
 The TLC analysis in Fig. 1 shows the different profiles of human and 
bovine milk saccharides. The HMS has oligosaccharide spots below the 
lactose spot, which was not observed in the BMS. This shows that 










Fig. 1 TLC analysis of partially purified HMS and BMS. F+L : 
fucose(4%) + lactose(4%), 2FL : 2-fucosyllactose (15 mg/ml), 3FL : 3-
fucosyllactose (15 mg/ml), HMS : human milk saccharides (30 mg/ml), 
BMS : bovine milk saccharides (30 mg/ml). Every spot was loaded 
with 1μl, except BMS and HMS (5 μl). The oligosaccharide spot in 






Growth of Bifidobacterium strains in the presence of fucosyl 
carbohydrates  
 
Fig. 2 shows the growth of each Bifidobacterium in MRS medium 
with 2FL, 3FL, HMS, and BMS as carbon sources. All of the 
experimental Bifidobacterium strains showed similar growth patterns in 
the presence of HMS and BMS probably because both HMS and BMS 
contained abundant amount of lactose. Interestingly, B. bifidum BGN4 
showed the best growth in the presence of 2FL and 3FL as a sole 
carbon source.  
When each culture broth was analyzed for the sugars, B. bifidum 
BGN4 shows the hydrolyzed monomers of fucosyl lactoses (fucose, 
galactose, and glucose) at the 3FL and 2FL groups (Fig. 3 : lane 4 in 
3FL and 2FL groups). This result suggests that B. bifidum BGN4 has 
the best hydrolyzing ability for fucosyl residues and lactose among the 
experimental bifidobacteria. At the HMS group, B. breve (Fig. 3 : lane 
2 in HMS group) revealed a light oligosaccharide spot after consuming 
all of the lactose which had initially covered the undigested 
oligosaccharides spots. These spots for oligosaccharide and lactose 
disappeared when B. bifidum BGN4 was cultured and produced a light 
orange spot for fucose (Fig. 3 : lane 4 in HMS group). It means that 
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fucosyl oligosaccharides contained in HMS was hydrolyzed and 
consumed by B. bifidum but not by B. breve. 
Fig. 4 shows the amount of released L-fucose in 5 µl of each culture 
broth. The 2FL and 3FL groups showed considerable level of released 
fucose in the culture broth of B. bifidum BGN4. The culture broth of 
the other strains did not show released fucose.  
The comparison of the released fucose by experimental 
Bifidobacterium between HMS and BMS revealed that only B. bifidum 
BGN4 released higher level of fucose in HMS than BMS. It confirms 
that HMS has higher level of FO than BMS which were efficiently 
hydrolyzed by B. bifidum BGN4. These results are consistent with the 
data obtained from Fig. 2 showing that B. bifidum BGN4 grew the best 
in the presence of 2, 3-FL and from Fig. 3 suggesting that B. bifidum 
BGN4 can hydrolyze FO. 
In the previous research, various strains of Bifidobacterum tested for 
its growth in HMO and FO. B. infantis showed noticeable growth in 
HMO and FO, while B. bifidum also showed growth but to a lower 
degree than B. infantis [2, 9, 11, 16, 17, 18, 21] which are different 
from this study. Several B. longum strains showed different pattern in 
the utilization of the HMO and FO [20] whereas B. longum strains 
which can use HMO contained common HMO utilization genes in their 
genomes [10]. These results suggest that the utilization ability of FO 
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and HMO is rather strain specific than species specific characteristics. 
The present study also showed that the degree of utilization of FO 
differs among different strains of Bifidobacterium. As shown in Fig. 2-4. 
B. bifidum BGN4 showed the noticeable utilization and hydrolysis of 
2FL, 3FL, and FO components contained in HMS. Other tested 
bifidobacteria did not show noticeable growth in FO. Accordingly, B. 
























Fig. 2 Growth curves of experimental bifidobacteria grown in MRS 
broth with different carbon sources. Each medium was added with 
2FL (2-fucosyllactose, 6 mg/ml), 3FL (3-fucosyllactose, 6 mg/ml), 
HMS (human milk saccharides, 20 mg/ml), BMS (bovine milk 
saccharides, 20 mg/ml). Each medium was incubated with B. 
adolescentis KCTC 3216 (●), B. breve KCTC 3419 (○), B. longum 
subsp. infantis KCTC 3249 (▼), B. bifidum BGN4 (△), B. longum 
subsp. longum RD47 (■). Control (□) was not inoculated. The data are 
expressed as the average of triplicate determinations. Bars of standard 
















Fig. 3 TLC analysis of saccharides in the culture broth after 
cultivation of several bifidobacteria strains in the medium with 
3FL, 2FL, and HMS. F+L : fucose(4%) + lactose(4%). 1 : B. 
adolescentis KCTC 3216, 2 : B. breve KCTC 3419, 3 : B. longum subsp. 
infantis KCTC 3249, 4 : B. bifidum BGN4, 5 : B. longum subsp. 
longum RD47, 6 : Control (non-fermented). MRS w/o glu : MRS 
without glucose, 3FL : MRS with 3-fucosyllactose (6 mg/ml), 2FL : 
MRS with 2-fucosyllactose (6 mg/ml), HMS : MRS with human milk 
saccharides (20 mg/ml). Each spot was loaded with 5 μl of culture 
broth except for F+L (1 μl). Hydrolyzed product of 2FL and 3FL by B. 
bifidum BGN4 are boxed and released fucose from HMS by B. bifidum 
BGN4 is indicated by black arrow. HMO in HMS which is not 




Fig. 4 Released fucose in the 5μl of media after culture of several 
Bifidobacterium strains. 2FL : 2-fucosyllactose (6 mg/ml), 3FL : 3-
fucosyllactose (6 mg/ml), HMS : human milk saccharides (20 mg/ml), 
BMS : bovine milk saccharides (20 mg/ml), MRS w/o glu : MRS 
without glucose. Each fucose assay was performed using 5μl of culture 
broth. The data are expressed as the average of triplicate determinations. 
Bars of standard deviations are also presented. Released fucose from 










Cloning and activity assessments of α-L-fucosidase genes 
 
Two open reading frames of putative α-L-fucosidase genes, 
BBB_0176 (5,880bp) and BBB_1341 (4,482bp), were identified in the 
full genome data of B. bifidum BGN4. The annotated sequences were 
used to design PCR primers, and to deduce the theoretical pI/MW 
(isoelectric point / molecular weight) using the ExPASy (The Expert 
Protein Analysis System, http://www.expasy.org). 
BBB_0176 was PCR amplified (Fig. 6, a) and digested with Hind Ⅲ 
and XhoⅠ. It was ligated with Hind Ⅲ and XhoⅠdigested pET21 to 
construct p0176 and transformed into E. coli BL21 (Fig. 5). It is 
expected to produce recombinant protein ‘AFL03772 + 6x His tag’ with 
MW and pI of 206 kDa and 5.45, respectively. BBB_1341 was PCR 
amplified (Fig. 6, b) and digested with XhoⅠ. It was ligated with Xho
Ⅰdigested pET21 to construct p1341 and transformed into E. coli 
BL21 (Fig. 5). It is also expected to produce recombinant protein 
‘AFL04933 + 6x His tag’ with MW and pI of 159 kDa and 5.15, 
respectively. Each recombinant E.coli BL21 strain harboring p0176 and 
p1341 was designated as E0176 and E131, respectively.   
The plasmid DNA purified from the two clones of α-L-fucosidase 
genes (p0176 and p1341) were digested by Bgl II for confirmation by 
band pattern and size estimation. The expected 11,316 bp band from the 
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p0176 (Fig. 6 : c) and 6,952 and 2,983bp bands from p1341 (Fig. 6 : d) 
were shown. 
The TLC assay in Fig. 7 and the fucose assay in Fig. 8 showed that 
the crude enzyme of BL21 harboring empty vector (Fig. 7 : 2, Fig. 8 : 
pET21) did not show fucose releasing activity for all substrates. On the 
other hand, the crude enzyme of E0176 (Fig.7 : 3, Fig. 8 : E0176) 
released fucose by hydrolyzing the α-(1→2) linkage of 2FL and α-
(1→3) linkage of 3FL. The crude enzyme of E1341 (Fig. 7 : 4, Fig. 8 : 
E1341) showed more than doubled hydrolyzing activity for the α-(1→3) 
linkages of 3FL compared to E0176, but not for 2FL. 
In the case of HMS, E0176 showed stronger hydrolysis activity 
compared to E1341 (Fig. 8), probably because E0176 can hydrolyze 
both α-(1→2) and α-(1→3) linkages of fucosylated residue of FO in 
HMO, whereas E1341 can only hydrolyze α-(1→3) linkages.  
As a result, the two recombinant α-L-fucosidases were found to 
hydrolyze two major FO, 2FL and 3FL, present in HMO. This 
observation was similar to that of the two α-L-fucosidases of B. bifidum 
JCM1254, which were previously shown to successfully utilize 







Fig. 5 Cloning strategy of each α-L-fucosidase genes (BBB_0176, 






Fig. 6 PCR amplification of two a-L-fucosidase genes from B. 
bifidum BGN4 and Bgl II digestion of p0176 and p1341. L : 1 kb 
DNA ladder, a : PCR amplified BBB_0176, b : PCR amplified 






Fig. 7 TLC of hydrolysis products of 2FL, 3FL, and HMS using 
crude enzyme of α-L-fucosidases obtained from recombinant E. 
coli BL21. F+L : fucose (4%) + lactose (4%), 1 : Distilled water, 2 : 
Cell free extract from BL21 harboring pET21a(+), 3 : Cell free extract 
from E0176, Cell free extract obtained from E1341, 2FL (2-
fucosyllactose, 15 mg/ml), 3FL (3-fucosyllactose, 15 mg/ml), HMS 
(human milk saccharides, 300 mg/ml). Two μl of substrates and 3μl of 
each crude enzyme were incubated at 37°C, 30min. Every spot was 




Fig. 8 Hydrolyzed fucose from 2FL, 3FL, and HMS by crude 
enzymes of each recombinant E. coli BL21. 
DW : Distilled water (control), pET21 : Cell free extract from BL21 
harboring pET21a(+), E0176 : Cell free extract from BL21 harboring 
p0176, E1341 : Cell free extract obtained from BL21 harboring p1341, 
2FL (2-fucosyllactose, 15 mg/ml), 3FL (3-fucosyllactose, 15 mg/ml), 
HMS (human milk saccharides, 300 mg/ml). Each fucose assay was 
performed using 5μl of reactant (2μl of substrates and 3μl of each crude 
enzyme, 37°C, 30min). The data are expressed as the average of 






Purification of α-L-fucosidases  
 
His-tag purification and gel filtration were conducted to purify the 
recombinant α-L-fucosidase. After the purification by his-tag column, 
AFL03772 (recombinant protein of α-L-fucosidase gene BBB_0176) 
showed a protein band with a molecular mass of around 200 kDa, 
which corresponds with the molecular mass of 206 kDa deduced from 
gene sequence. However, the his-tag purified protein yielded two 
major bands on SDS-PAGE (Fig. 9 : lane C5). This eluted fraction was 
further purified to obtain one major band via gel filtration with 
Superdex 200 column (Fig. 9 : lane 6).  
In the case of AFL04933 (recombinant protein of α-L-fucosidase gene 
BBB_1341), crude enzyme was used for the characterization because of 












Fig. 9 SDS-PAGE of AFL03772 (recombinant protein of α-L-
fucosidases gene BBB_0176) purified by His-tag purification and 
gel filtration. L : ladder, 1 : Crude enzyme of BL21 harboring p0176, 
2 : Elution fraction 1, 3 : Flow through, 4 : Elution fraction 2, 5 : 
Elution fraction 3, C2 : Concentrated 2, C4 : Concentrated 4, C5 : 










The effects of temperature and pH on α-L-fucosidase activities 
 The optimal temperature of α-L-fucosidases were determined to be 
35°C (Fig. 10 : a) for AFL03772 and 45°C (Fig. 10 : c) for AFL04933, 
respectively, when investigated in the pB buffer (20 mM, pH 7.8). 
The effect of pH on AFL03772 was investigated from 4.05 to 7.48, 
and the optimal pH was observed at 6 - 6.54 (Fig. 10 : b). In the case of 
AFL04933, the optimal pH was 10 when examined in the range of 7 - 
















Fig. 10 Effects of temperature and pH on the activities of 
AFL03772 (recombinant protein of BBB_0176) and crude AFL 
04933 (recombinant protein of BBB_1341). a : Effect of temperature 
on AFL03772, b : Effect of pH on AFL03772, c : Effect of temperature 
on AFL04933, d : Effect of pH on AFL04933. The data are expressed 
as the average of triplicate determinations. Bars of standard deviations 










In this research, the selective utilization of fucosylated 
oligosaccharides - which are a major component of HMO - has been 
confirmed for B. bifidum BGN4. In addition, the corresponding genes 
of two α-L-fucosidases which are essential for the hydrolysis and 
utilization of fucosylated HMO were expressed in E. coli BL21 and 
purified for characterization. This is the first report to confirm the 
activity and characteristics of the annotated hypothetical fucosidase 
genes in the genome of B. bifidum BGN4. Also, the crucial role of α-L-
fucosidases for the preferential utilization of FO and successful growth 
of B. bifidum BGN4 in FO was confirmed. B. bifidum BGN4 may 
successfully colonize the intestinal tracts of the breast-fed infants by 
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Bifidobacterium은 모유 영양아의 장내에서 우세한 성장을 보
이는 유익균이며, 아기 장내 균총의 균형 유지에 유익한 영향
을 미친다. 모유 올리고당 (Human milk oligosaccharide, HMO)은 
모유에서 세번째로 많은 고형 성분(15 g/L)이며  퓨코실 올리고
당이 (fucosylated oligosaccharides, FO) 약 75%의 높은 비율로 존
재한다. 따라서 모유에서 소화되지 않고 대장에 도달한 퓨코실 
올리고당을 이용할 수 있는 Bifidobacterium은 모유 영양아의 
장내에서 선택적인 성장이 가능할 것으로 생각된다. 
 몇 종류의 Bifidobacterium 에 대하여 모유의 당과, 인공적으
로 합성된 모유 퓨코실 올리고당의 주요 구조 2가지 (2-
fucosyllactose, 3-fucosyllactose) 의 이용능이 측정되었다. 실험한 
Bifidobacterium 중 B. bifidum BGN4 가 2FL과 3FL에 의해 선택
적으로 성장이 촉진되었으며 모유 당에서 fucose를 가수분해하
였다.  
이전에 보고된 B. bifidum BGN4의 유전체 서열에서 퓨코실 올
리고 이용에 필수적인 효소인 α-L-fucosidase로 예상되는 유전
자 2개 (BBB_0176 and BBB_1341) 의 서열이 확인되었다. 이들
을 클로닝하여 E. coli BL21에서 발현시킴으로서 각각의 유전자
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가 발현된 효소 단백질의 활성과 특성을 확인하였다. 
BBB_0176 유전자가 발현된 AFL03772 단백질은 2FL의 α-(1→2) 
과 3FL의 α-(1→3) 결합에 대해 가수분해능을 보였으며, 
BBB_1341 유전자가 발현된 AFL04933 단백질은 3FL의 α-(1→3) 
결합에 대한 가수분해능이 확인되었다. 본 연구에서는 B. 
bifidum BGN4 가 모유 속의 퓨코실 올리고 이용에 필요한 α-L-
fucosidase 효소를 지니고 있다는 것을 확인함에 따라 B. 
bifidum BGN4를 모유 영양아의 장내에서 선택적인 성장이 가
능한 유익균으로서 이용할 수 있는 가능성을 제시하였다.  
 
주요어 : Bifidobacterium bifidum BGN4, α-L-fucosidase 
퓨코실 모유 올리고당 이용능 
학   번 : 2013-21513 
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